Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DDO | Q99489 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22531723 | 0.85 | GRM5 (0.38) | GRM5CYP2A6 | |
| SCHEMBL31014678 | 0.82 | GRM5 (0.34) | GRM5CYP2A6 | |
| SCHEMBL9956785 | 0.79 | GRM5 (0.50) | GRM5CYP2A6 | |
| SCHEMBL3664236 | 0.77 | KDM4E (0.33) | KDM4EMEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL12938274 | 0.76 | GRM5 (0.39) | GRM5 | |
| SCHEMBL503406 | 0.76 | GRM5 (0.33) | GRM5CYP2A6 | |
| SCHEMBL29434830 | 0.76 | GRM5 (0.40) | GRM5 | |
| SCHEMBL1476913 | 0.76 | GRM5 (0.40) | GRM5 | |
| SCHEMBL1476678 | 0.76 | RAF1 (0.38) | GRM5 | |
| SCHEMBL1477377 | 0.76 | GRM5 (0.49) | KDM4EGRM5CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360104-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2024-10-31 | — | — | US | disclosed |
| EP-4330253-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022232088-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| EP-3127900-B1 | ALKYNYL INDAZOLE DERIVATIVE AND USE THEREOF | SENJU PHARMA CO (JP) | 2017-10-18 | — | — | EP | disclosed |
| EP-2668179-B1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2017-08-16 | — | — | EP | disclosed |
| EP-2668179-B1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2017-08-16 | — | — | EP | disclosed |
| US-9617222-B1 | Alkynyl indazole derivative and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2017-04-11 | — | — | US | disclosed |
| US-9617222-B1 | Alkynyl indazole derivative and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2017-04-11 | — | — | US | disclosed |
| US-20170096400-A1 | ALKYNYL INDAZOLE DERIVATIVE AND USE THEREOF | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2017-04-06 | — | — | US | disclosed |
| US-20170096400-A1 | ALKYNYL INDAZOLE DERIVATIVE AND USE THEREOF | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2017-04-06 | — | — | US | disclosed |
| WO-2011092197-A1 | 5-ALKYNYL PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011092198-A1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
| EP-2323992-A1 | 5-ALKYNYL-PYRIMIDINES | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | disclosed |
| US-20110098275-A1 | 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098275-A1 | 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | US | disclosed |
| WO-2010122069-A1 | 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010012740-A1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | WO | disclosed |
| EP-2146716-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008131227-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360104-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD4, TEAD1, TEAD2 | KDM4E 2554/4885MEN1 2148/4885ALDH1A1 2261/4885 |
| US-20110098275-A1 | 5-ALKYNYL-PYRIDINES | MKI67, KIT, CCNA1 | KDM4E 494/4885MEN1 684/4885ALDH1A1 169/4885 |
| US-20170096400-A1 | ALKYNYL INDAZOLE DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | KDM4E 3477/4885MEN1 4422/4885ALDH1A1 551/4885 |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, PRKACA, BRAF | KDM4E 1040/4885MEN1 223/4885ALDH1A1 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.